Charlie Alvarez Appointed Alliance Family of Companies CEO

Charlie Alvarez has been appointed the new Chief Executive Officer of Alliance Family of Companies, effective immediately. Charlie Alvarez brings more than 30 years of healthcare leadership experience and most recently served as Chief Executive Officer of DCI Health Technologies, Inc.

Charlie Alvarez succeeds J. Randall Keene, who has served as interim CEO since June 2019. Keene will continue in his role as Chairman of the Alliance Board of Directors.

In making the announcement, Keene cited Alvarez’s extensive strategic experience and entrepreneurial track record. “Charlie is the right leader for this role, especially in the current environment,” said Keene. “After an extensive search, Charlie presented the perfect blend of industry experience and executive leadership to carry Alliance into the future. He also comes to the company with a strong belief in our core values, which are to provide the best solutions for the patient, provider, and payor. I am confident he will continue to drive Alliance’s focus on value-based healthcare delivery by providing accessible, high-quality neurodiagnostic services in the home, as these services shift out of the hospital setting.”

As Chief Executive Officer of Foxconn’s DCI Health Technology, Inc., a multinational health technology company, Alvarez was responsible for launching the company in the United States and driving its revenue and profitability growth. He joined DCI in 2017, when his previous company, Sotera Wireless Inc. was acquired by Foxconn. Alvarez had joined Sotera Wireless in 2014 as Senior Vice President of Sales and Marketing where he was responsible for growing sales and revenue. Sotera is a medical device company that specializes in body worn vital signs monitoring. Within two years, Alvarez grew the client base from seven hospitals to more than 55 and grew revenue by more than 75 percent, year-over-year.

Prior to Sotera, Alvarez was President and Co-Founder of Watermark Medical, a privately held sleep diagnostics and therapy company. Alvarez was President through the acquisition of SleepMed, Inc, in 2012, a company that also provided EEG services. At Watermark, Charlie pioneered the home sleep testing market and grew the company to become the market leader in five short years. Before co-founding Watermark, Alvarez held various leadership positions at CardioNet (Biotel), the world’s largest remote cardiac monitoring company and PSS/World Medical, now McKesson.

“I’m excited to be joining the Alliance team,” said Alvarez. “I believe Alliance has a great business model, high-quality services and a robust R&D pipeline to position it for high growth over the next several years. I look forward to applying my experience in the ever-changing medical marketplace to lead the company in the development of technology and services that help provide better healthcare solutions. Alliance is poised for hyper-growth as we prepare for the upturn in business as this crisis starts to wane.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”